-+ 0.00%
-+ 0.00%
-+ 0.00%

Cardiff Oncology updates Phase 2 onvansertib data in first-line RAS-mutated mCRC trial

PUBT·05/21/2026 21:02:32
Listen to the news
Cardiff Oncology updates Phase 2 onvansertib data in first-line RAS-mutated mCRC trial
  • Cardiff Oncology scheduled an investor webcast for June 3, 2026 to review updated Phase 2 CRDF-004 data on onvansertib in first-line RAS-mutated metastatic colorectal cancer.
  • The updated results will be presented in a rapid oral session at the 2026 ASCO Annual Meeting on June 2, 2026, building on data previously presented in January 2026.
  • The Phase 2 trial showed the onvansertib combination produced better outcomes than standard treatment alone, supporting the company’s plan to move the 30 mg dose into a registrational trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211700PRIMZONEFULLFEED9724812) on May 21, 2026, and is solely responsible for the information contained therein.